The FDA is questioning CEPH’s data on the co-primary endpoint called Patient Global Impression of Severity, which is subjective. This would seem to be a case where an SPA would have been helpful.I don't understand what do you mean, the phase III trial for Nuvigil in jet-lag was conducted under an SPA.